Mandate

Vinge advises Industrifonden in connection with an investment in MinervaX

Vinge has advised Industrifonden in connection with its investment in MinervaX.

MinervaX has developed a vaccine against streptococcus and in connection with the financing round has procured a total of MEUR 47.4 from a syndicate consisting of Industrifonden, Sanofi Ventures, Wellington Partners and Adjuvant Capital.

Vinge’s team primarily consisted of Johan LarssonSara Strandberg and Stojan Arnerstål.

Related

Vinge has assisted PulPac in connection with it obtaining a €20 million financing from the European Investment Bank

Vinge has assisted Gothenburg-based sustainable packaging technology company PulPac in connection with it obtaining a €20 million (around 220 million Swedish kronor) financing from the European Investment Bank (EIB).
July 18, 2025

Vinge has advised Behold Ventures in the fundraising of Behold Ventures’ first-time fund

Behold Ventures held its final closing on 27 June 2025, thereby securing investor commitments to its first-time fund amounting to approximately SEK 550 million from an international investor base, comprising the European Investment Fund (EIF), among others.
July 10, 2025

Vinge advises Main Capital in connection with the sale of Alfa eCare

Vinge has advised Main Capital in connection with the sale of Alfa eCare Holding AB and its subsidiaries (“Alfa eCare”) to SDB Groep B.V. (“SDB”)
July 10, 2025